1.2392
Werewolf Therapeutics Inc Borsa (HOWL) Ultime notizie
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know - MSN
Werewolf Therapeutics Adopts New Bylaws and Elects Directors - TipRanks
Two Sigma Investments LP Sells 87,168 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics to Participate in the BIO International Convention - GlobeNewswire
Jane Street Group LLC Acquires 39,564 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Two Sigma Advisers LP Sells 117,200 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Sold by Millennium Management LLC - Defense World
Deutsche Bank AG Buys 83,172 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Northern Trust Corp Acquires 16,640 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Bank of America Corp DE Lowers Stock Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics Announces Q1 2025 Financial Results - MSN
Werewolf Therapeutics Leaders to Reveal Latest Cancer Treatment Progress at Major Healthcare Conference - Stock Titan
Werewolf Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference on June 5, 2025 - Nasdaq
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference - GlobeNewswire
D. E. Shaw & Co. Inc. Makes New Investment in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics (HOWL) Price Target Lowered by BofA, Buy Rating Maintained | HOWL Stock News - GuruFocus
Werewolf Therapeutics (HOWL) Price Target Lowered by BofA, Buy R - GuruFocus
Werewolf Therapeutics (HOWL) Stock Price, News & Analysis - MarketBeat
Werewolf Therapeutics’ SWOT analysis: innovative platform drives stock potential By Investing.com - Investing.com Nigeria
Werewolf Therapeutics’ SWOT analysis: innovative platform drives stock potential - Investing.com Australia
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 - GlobeNewswire
Breakthrough Skin Cancer Treatment: Patient Cancer-Free After 1 Year in Revolutionary IL-2 Drug Trial - Stock Titan
Dimensional Fund Advisors LP Cuts Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics Receives Nasdaq Deficiency Notice - TipRanks
Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit - GlobeNewswire
Wedbush Cuts Werewolf Therapeutics (NASDAQ:HOWL) Price Target to $6.00 - Defense World
Werewolf Therapeutics First Quarter 2025 Earnings: US$0.40 loss per share (vs US$0.39 loss in 1Q 2024) - Yahoo Finance
Wedbush Adjusts Price Target on WEREWOLF THERAPEUTICS (HOWL) to USD 6.00 | HOWL Stock News - GuruFocus
H.C. Wainwright cuts Werewolf Therapeutics target to $10 By Investing.com - Investing.com Nigeria
H.C. Wainwright cuts Werewolf Therapeutics target to $10 - Investing.com Australia
Wedbush Adjusts Price Target on Werewolf Therapeutics to $6 From $8, Maintains Outperform Rating - marketscreener.com
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Werewolf Therapeutics Reports Q1 2025 Financial Results - TipRanks
Werewolf Therapeutics (HOWL) Advances Clinical Trials and Expands Educational Initiatives | HOWL Stock News - GuruFocus
Werewolf Therapeutics Announces Progress in Clinical Trials and Financial Updates for Q1 2025 - Nasdaq
Renaissance Technologies LLC Decreases Holdings in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
JPMorgan Chase & Co. Raises Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
HOWLWerewolf Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Werewolf Therapeutics (HOWL) Showcases Innovative IBD Treatment Developments | HOWL Stock News - GuruFocus
Werewolf Therapeutics reports progress on IBD treatment - Investing.com Australia
Werewolf Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):